निर्माट्रेल्विर और रिटोनाविर और विन्क्रिस्टिन का इंटरैक्शन

Anticancer drugs abemaciclib, ceritinib, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, vincristine ↑ anticancer drugs Avoid co-administration of encorafenib or ivosidenib due to potential risk of serious adverse events such as QT interval prolongation.

Co-administration of vincristine and vinblastine may lead to significant hematologic or gastrointestinal side effects.

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided.

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided.

Patients should be frequently monitored for adverse reactions with concomitant use of moderate CYP3A inhibitors (e.g., fluconazole) with vincristine sulfate.